经皮5T细胞淋巴瘤(CTCL)是一种以恶性T细胞浸润皮肤并具有潜在扩散能力的疾病，由于疾病的异质性、治疗抵抗性和缺乏有效和标准化的诊断和预后临床工具，导致其诊断和治疗一直是一个具有挑战性的问题。目前，CTCL的诊断实际上依赖于临床表现、组织病理学和免疫组化技术。这些方法在敏感性和特异性方面都存在局限性。幸运的是，流式细胞术、聚合酶链式反应、高通量测序和其他分子技术的最新进展显示出提高CTCL诊断和治疗的希望。其中包括通过测序进行T细胞受体克隆型鉴定，以更早地检测CTCL的病程，并通过单细胞RNA测序识别常见CTCL发病机制相关的基因表达模式。对这些技术的研究经验为CTCL的诊断和治疗策略提供了新的见解。Copyright © 2023 Lefebvre, Borcherding, Reis, Mou, Liu and Jabbari.

Cutaneous 5T cell lymphoma (CTCL), characterized by malignant T cells infiltrating the skin with potential for dissemination, remains a challenging disease to diagnose and treat due to disease heterogeneity, treatment resistance, and lack of effective and standardized diagnostic and prognostic clinical tools. Currently, diagnosis of CTCL practically relies on clinical presentation, histopathology, and immunohistochemistry. These methods are collectively fraught with limitations in sensitivity and specificity. Fortunately, recent advances in flow cytometry, polymerase chain reaction, high throughput sequencing, and other molecular techniques have shown promise in improving diagnosis and treatment of CTCL. Examples of these advances include T cell receptor clonotyping via sequencing to detect CTCL earlier in the disease course and single-cell RNA sequencing to identify gene expression patterns that commonly drive CTCL pathogenesis. Experience with these techniques has afforded novel insights which may translate into enhanced diagnostic and therapeutic approaches for CTCL.Copyright © 2023 Lefebvre, Borcherding, Reis, Mou, Liu and Jabbari.